Co-diagnostics, inc. announces additional grant award for tuberculosis test in development

Company to use funds awarded by the bill & melinda gates foundation toward the tuberculosis test for its co-dx™ pcr platform salt lake city , nov. 2, 2023 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced a grant awarded by the bill & melinda gates foundation to support the tuberculosis (tb) test in development, designed to be run on the upcoming co-dx™ pcr platform*. the amount awarded is $8.976 million.
CODX Ratings Summary
CODX Quant Ranking